“The pharmacology of sigma-1 receptors”. Pharmacology & Therapeutics (2009), journal homepage.
Tangui Maurice, Tsung-Ping Su
View Paper

“Anti-amnesic and neuroprotective activities of ANAVEX2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligand, in pharmacological and pathological models of amnesia”. Poster presentation in The Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD), July 11-16 in Vienna, Austria.
Vanessa Villard, Julie Espallergues, Alexandre Vamvakides and Tangui Maurice
View Abstract

“Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid beta25-35-Induced Toxicity in Mice”. Publication in Neuropsychopharmacology December 2008.
Villard V, Espallergues J, Keller E, Alkam T, Nitta A, Yamada K, Nabeshima T, Vamvakides A, Maurice T
View Paper

“The neuroprotective action of ligands acting at the sigma-1 chaperone protein involves regulation of the expression of IP3 receptor subtypes and SerCa pumps”. Poster presentation in Neuroscience 2008, Nov. 15-19 in Washington, DC.
Vanessa Villard, Fanny Malhaire-Ferreux, François Monnet, Alexandre Vamvakides, Tangui Maurice
View Poster

“Neuroprotective effects of activators/agonists of the sigma-1 chaperone protein against amyloid toxicity in a mouse model”. ICAD (International conference on Alzheimer’s Disease) 26-31 July 2008,Chicago,USA
Tangui Maurice, Vanessa Villard, Johann Meunier, Emeline Keller, Fanny Malhaire, Alexandre Vamvakides
View Poster

“The proteome profile of two cell lines and their xenografts isolated from a patient with clear cell sarcoma (soft tissue melanoma)”. Cancer Genomics & Proteomics 5: 175-238 (2008).
Dimas K., Tsimplouli C., Anagnostopoulos A.K., Mahaira L., Iliopoulou E., Perez S., Vougas K., Tsangaris G.
View Paper

“Neuroprotective activity of ANAVEX 1-41, an aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, against amyloid beta(25-35) peptide toxicity in mice”. Poster presentation in Neuroscience 2007, Nov. 3-7 in San Diego, Calif.
Vanessa Villard, Johann Meunier, Alexandre Vamvakides, Tangui Maurice
View Poster

“Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and pathological models of amnesia”. Poster presentation in Neuroscience 2007, Nov. 3-7 in San Diego, Calif.
Johann Meunier, Vanessa Villard, Julie Espallergues, Alexandre Vamvakides and Tangui Maurice
View Poster

“Anavex 7-1037, a novel small synthetic sigma ligand, induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in SCID mice.” Poster Presentation in the 15th Euroconference on Apoptosis & 4th Training course on 'Concepts and Methods in Programmed Cell Death', October 26-31, 2007 in Portoroz, Slovenia.
Mahaira G Louisa, Humaira Khan, Chrisiida Tsiblouli, Pantazis Panayotis, Karamitopoulou Evangelia, Vamvakides Alexandros, and Dimas Konstantinos
View Poster

“Involvement of the sigma1 (s1) receptor in the antiamnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX 1-41”. British Journal of Pharmacology (2007).
Espallergues J., Lapalud P., Christopoulos A., Avlani V.A., Sexton P.M., Vamvakides A. and Maurice T.
View Paper

“Anti-amnesic and neuroprotective potentials of aminotetrahydrofuran derivatives, mixed muscarinic/sigma1 (s1) ligands, against amyloid beta25-35 peptide toxicity in mice”. Poster Presentation in the 8e Colloque de la Société des Neurosciences, May 22-25, Montpellier, France (2007).
Vanessa Villard, Julie Espallergues, Alexandre Vamvakides & Tangui Maurice
View Poster

“Involvement of the sigma1 (s1) receptor in the anti-amnesic effects of the aminotetrahydrofuran derivative AE14”. Poster Presentation in Neuroscience 2006, October 14-18, Atlanta, USA.
Julie Espallergues, Priscilla Lapalud, Alexandre Vamvakides, and Tangui Maurice
View Poster

“Action mechanism of anticonvulsant and anti-immobility (forced swim) effects of 3', 4'-dihydro-N, N-dimethylspiro-[9H-fluorene-9, 2' (5'H) furane]-3'-methanamine (AE37F)”. Ann Pharm Fr.; 62(1):49-55 (French) (2004).
Vamvakides A, Antoniou K, Daifoti Z.
View abstract in PubMed
View Publication

“Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer’s disease or inappropriate tactics?”. Ann Pharm Fr.; 61(3):207-10 Review (French) (2003).
Vamvakides A.
View abstract in PubMed

“Mechanism of action of tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanemethanamine, a putative nootropic, anti-epileptic and antidepressant compound”. Ann Pharm Fr.; 60(6):415-22. (French) (2002).
Vamvakides A.
View abstract in PubMed
View Publication

“Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine (AE37): common action mechanism?” Ann Pharm Fr.; 60(2):88-92. Review (French) (2002).
Vamvakides A.
View abstract in PubMed